Migraine’s Comorbidities: A Look at Associated Conditions
Interview Notes – COMING SOON
- Peter McAllister, MD, FAAN
Treatments Mentioned – COMING SOON
Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.
Peter McAllister, MD, FAAN
Medical Director
New England Institute for Neurology & Headache
Dr. Peter McAllister is board certified in neurology and headache medicine. He is the medical director of the New England Institute for Neurology and Headache and chief medical officer of the New England Institute for Clinical Research and Ki Clinical Research in Stamford, Connecticut.
Dr. McAllister is an associate professor of neurology at the Yale University School of Medicine and clinical professor of neurology and anatomy at the Frank H. Netter School of Medicine at Quinnipiac University. He is a fellow of the American Academy of Neurology and an executive board member of the Headache Cooperative of New England.
He is recognized as a “Top Neurologist” by U.S. News & World Report and also listed as a “Top Doc” in Connecticut, metropolitan New York City, and Fairfield County.
Dr. McAllister lectures internationally, has been a principal investigator on over 350 clinical trials, and has authored more than 100 articles and book chapters in the lay and scientific press.
For a limited time get up to 27% OFF all the 2025 interviews, videos, audio, transcripts, and more. Why upgrade?
- Can’t attend live? Watch anytime
- Prefer reading or listening? Get transcripts and audio
- Want to dive deeper? Explore the additional footage & resources
- Need ongoing support? Reference expert advice year-round
- Lifetime access to 2025, no annual fee
- Act now, early-bird offer ends March 19th!